OpenBit ResearchOpenBit
中文

What's driving United Therapeutics (UTHR)

Compiled from the engine's research, source claims and public filings in this dossier. Each has its own data date, listed below.

Research summary

Will UTHR’s patent enforcement constrain Liquidia competition?

Why it matters now

Patent enforcement can protect UTHR’s competitive position and revenue opportunity against Liquidia.

Next checkpoint

UTHR earnings (expected 2026-11-04)

This checkpoint sits on a shared driver. The engine does not explain how it carries over to UTHR, so treat it as context, not a verified checkpoint for this company.

What would break the thesis

A final judgment that removes or materially reverses the infringement finding would break the mechanism.

Research drivers

  • Will UTHR’s patent enforcement constrain Liquidia competition?

    Bullish · Emerging · Updated

    The court has ruled that Liquidia infringes claims 1 and 14 of UTHR’s '327 patent, while the final judgment remains pending.

Source claims

Source labels are as recorded in our data. The dossier does not include links to the originals, so these are not verified quotations.

  • A judge upheld claims 1 and 14 of United Therapeutics' '327 patent and ruled that Liquidia infringes the patent.

    Relayed by: Benzinga · Event date on record:

  • Final judgment in the United Therapeutics patent case against Liquidia is due within one week.

    Relayed by: Benzinga · Ingestion date (event date unconfirmed):

Related sectors

Biotech

Filed holders

This dossier has no filed holders to show. That does not mean no institution holds it.